Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
6
×
boston top stories
life sciences
national blog main
national top stories
6
×
opioid
6
×
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer
clinical trials
abbvie
deals
drug prices
fda
startups
bristol-myers squibb
cancer immunotherapy
celgene
cell therapy
crisis
What
roundup
bio
drug
ahead
approval
asco
conference
fda
abbvie’s
advanced
alkermes
alnylam’s
ambien
american
annual
antipsychotic
attendees
attention
barbecuing
benefits
bff
biogen’s
biopharmaceutical
biotech
branded
camping
camp’s
cancer
cardiologist
cash
caveats
center
check
chicago
choices
cholesterol
city
clinical
combinations
commissioner
Language
unset
Current search:
opioid
×
" boston blog main "
×
" national top stories "
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
4 years ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
4 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More